U.S. flag

An official website of the United States government

PMC Full-Text Search Results

Items: 4

1.
Figure 3

Figure 3. From: Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent.

Immunofluorescence staining of gpNMB in MDA-MB-468 (A) and MDA-MB-231 (B) tumor sections. Scale bars represent 50 μm. DAPI stained nuclei are marked blue and gpNMB stained (positive) membrane fragments are shown as green.

Bernadette V. Marquez-Nostra, et al. Oncotarget. 2017 Nov 28;8(61):104303-104314.
2.
Figure 4

Figure 4. PET/CT imaging of [89Zr]DFO-CR011 in PDX models of TNBC at 7 days post-injection. From: Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent.

(A) Maximum Intensity Projections of WHIM-4E and WHIM-5F. Mean SUV are shown as values next to the tumors. (B) Correlative study between mean SUV in the tumor and gpNMB expression via ELISA.

Bernadette V. Marquez-Nostra, et al. Oncotarget. 2017 Nov 28;8(61):104303-104314.
3.
Figure 2

Figure 2. PET/CT imaging of [89Zr]DFO-CR011 in TNBC xenograft models at 4 days post-injection. From: Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent.

(A) Maximum Intensity Projections of representative mice. (B) Mean SUV in tumors at 4 and 7 days show significantly higher [89Zr]DFO-CR011 uptake in MDA-MB-468 at both time points. (C) Biodistribution study post PET imaging at 7 days. Similar [89Zr]DFO-CR011 uptake in normal organs were observed for both xenograft models.

Bernadette V. Marquez-Nostra, et al. Oncotarget. 2017 Nov 28;8(61):104303-104314.
4.
Figure 1

Figure 1. Pharmacologic properties of [89Zr]DFO-CR011 in vitro. From: Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent.

(A) Competitive binding study in MDA-MB-468. (B) Cell uptake and blocking studies in cell lines with varying gpNMB expression. (C) The cell uptake of [89Zr]DFO-CR011 is correlated with gpNMB expression in whole cell lysates (Pearson’s r = 0.95). (D) Rate of cellular internalization at 37°C showed 50% of bound [89Zr]DFO-CR011 internalized within 30 – 60 min. The reaction at 4°C significantly reduced cellular internalization.

Bernadette V. Marquez-Nostra, et al. Oncotarget. 2017 Nov 28;8(61):104303-104314.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center